[go: up one dir, main page]

MX2010007150A - Formulaciones del factor de von-willebrand recombinante. - Google Patents

Formulaciones del factor de von-willebrand recombinante.

Info

Publication number
MX2010007150A
MX2010007150A MX2010007150A MX2010007150A MX2010007150A MX 2010007150 A MX2010007150 A MX 2010007150A MX 2010007150 A MX2010007150 A MX 2010007150A MX 2010007150 A MX2010007150 A MX 2010007150A MX 2010007150 A MX2010007150 A MX 2010007150A
Authority
MX
Mexico
Prior art keywords
formulations
recombinant vwf
vwf formulations
recombinant
rvwf
Prior art date
Application number
MX2010007150A
Other languages
English (en)
Inventor
Hans-Peter Schwarz
Peter Turecek
Kurt Schnecker
Peter Matthiessen
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007150(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2010007150A publication Critical patent/MX2010007150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona formulaciones farmacéuticas, estables a largo plazo, del Factor de von-Willebrand recombinante (rVWF) y métodos para elaborar y administrar dichas formulaciones.
MX2010007150A 2007-12-28 2008-12-23 Formulaciones del factor de von-willebrand recombinante. MX2010007150A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1741807P 2007-12-28 2007-12-28
US1788107P 2007-12-31 2007-12-31
PCT/US2008/088201 WO2009086400A2 (en) 2007-12-28 2008-12-23 Recombinant vwf formulations

Publications (1)

Publication Number Publication Date
MX2010007150A true MX2010007150A (es) 2010-09-03

Family

ID=40591819

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007150A MX2010007150A (es) 2007-12-28 2008-12-23 Formulaciones del factor de von-willebrand recombinante.

Country Status (15)

Country Link
US (2) US20090192076A1 (es)
EP (2) EP2244814B1 (es)
JP (3) JP5784907B2 (es)
KR (2) KR20160091434A (es)
CN (2) CN101952016A (es)
AR (1) AR069989A1 (es)
AU (1) AU2008345135C1 (es)
BR (1) BRPI0821474B8 (es)
CA (1) CA2710762A1 (es)
ES (1) ES2887187T3 (es)
MX (1) MX2010007150A (es)
NZ (1) NZ586383A (es)
SG (2) SG187410A1 (es)
TW (3) TWI600437B (es)
WO (1) WO2009086400A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652782B2 (en) * 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US11197916B2 (en) * 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2887187T3 (es) 2007-12-28 2021-12-22 Takeda Pharmaceuticals Co Formulaciones de VWF recombinante
KR101772674B1 (ko) * 2008-10-21 2017-09-01 박스알타 인코퍼레이티드 동결건조된 재조합 ｖｗｆ 제제
US9062299B2 (en) 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
CA2780542C (en) 2009-11-13 2020-03-24 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
NZ600978A (en) * 2009-12-22 2014-08-29 Celldex Therapeutics Inc Vaccine compositions
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI505838B (zh) * 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
HRP20180962T1 (hr) * 2011-06-10 2018-10-19 Baxalta GmbH Liječenje bolesti zgrušavanja primjenom rekombinantnog vwf
CN109111526A (zh) 2012-01-12 2019-01-01 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
BR112014019901A8 (pt) 2012-02-15 2018-01-02 Biogen Idec Inc Proteínas de fator viii recombinante
HUE047088T2 (hu) 2012-07-11 2020-04-28 Bioverativ Therapeutics Inc VIII. faktor komplex XTEN-nel és von willebrand-faktor fehérjével, és alkalmazásai
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
HUE059820T2 (hu) 2014-01-10 2022-12-28 Bioverativ Therapeutics Inc VIII-as faktor kimérafehérjéi és azok alkalmazása
PL3158055T3 (pl) * 2014-06-13 2020-03-31 Csl Limited Ulepszone wytwarzanie rekombinowanego czynnika von Willebranda w bioreaktorze
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
MX2018015639A (es) 2016-06-27 2019-04-11 Baxalta Inc Estabilizador de jeringa.
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
AU2018298233B2 (en) 2017-07-07 2025-04-24 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
CN107966567B (zh) * 2017-11-21 2018-12-18 浙江夸克生物科技有限公司 一种触珠蛋白测定试剂盒
EA202092223A1 (ru) * 2018-03-21 2021-02-10 Баксалта Инкорпорейтед Разделение vwf и пропептида vwf хроматографическими методами
HRP20250709T1 (hr) 2018-05-18 2025-08-15 Bioverativ Therapeutics Inc. Postupci liječenja hemofilije a
US12128090B2 (en) 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
EP4097145B1 (en) * 2020-01-30 2026-01-28 Leukocare Ag Reduction of adsorption
US20230125871A1 (en) * 2020-03-18 2023-04-27 Gi Innovation, Inc. Fusion protein preparation comprising il-2 and cd80 proteins
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA7972A (en) * 1877-10-05 Edward M. Lowdon Improvements in lamps
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
EP0590048B1 (en) * 1991-06-20 2004-12-01 Aventis Behring L.L.C. A process for preparing therapeutic fragments of von willebrand factor
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
US20010046487A1 (en) * 1994-12-30 2001-11-29 Roser Bruce J. Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
AU3671197A (en) 1996-07-19 1998-02-10 Regents Of The University Of Michigan, The Dna encoding canine von willebrand factor and methods of use
SE9604296D0 (sv) 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
DE10043124A1 (de) * 2000-08-31 2002-03-14 Max Delbrueck Centrum Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase
DE60137950D1 (de) 2000-10-02 2009-04-23 Novo Nordisk Healthcare Ag Verfahren zur herstellung vitamin-k-abhängiger proteine
WO2002030463A2 (en) * 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
JP2007519623A (ja) * 2003-12-19 2007-07-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの安定化された組成物
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
FR2874216B1 (fr) 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044421B4 (de) * 2004-09-14 2010-06-24 Biotest Ag Verfahren zur Trennung eines von Willebrand Faktors mit einer spezifischen VWF-Aktivität von wenigstens 50 E/mg VWF-Antigen von einem von Willebrand Faktor mit niedriger Aktivität und Verwendung von Hydroxylapatit dafür
EP1835938B1 (en) * 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
GB0509443D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbents for factor VIII and von willebrand's factor
EP2264162A1 (en) * 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
CA2612937C (en) * 2005-07-22 2014-05-06 Amgen Inc. Concentrated protein lyophilates, methods, and uses
JP5364382B2 (ja) * 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
WO2008015187A1 (en) 2006-08-01 2008-02-07 Telefonaktiebolaget Lm Ericsson (Publ) User preferences in interactive personal television
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US20100137211A1 (en) * 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
CA2683317C (en) * 2007-04-26 2014-12-16 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
KR20100019999A (ko) 2007-06-13 2010-02-19 체에스엘 베링 게엠베하 출혈 장애의 치료법 및 예방 처치에 있어서의 혈관외 투여용 ｖｗｆ 안정화된 ｆｖｉｉｉ 제제 및 ｆｖｉｉｉ 무함유 ｖｗｆ 제제의 용도
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
ES2887187T3 (es) 2007-12-28 2021-12-22 Takeda Pharmaceuticals Co Formulaciones de VWF recombinante
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
JP2012508172A (ja) * 2008-11-03 2012-04-05 バイエル・ヘルスケア・エルエルシー 血友病の治療方法
EP2393501A1 (en) * 2009-02-05 2011-12-14 Pierre Philippart Method and means for producing tissues and tissues obtained

Also Published As

Publication number Publication date
TW201438763A (zh) 2014-10-16
KR20100098693A (ko) 2010-09-08
US20150216983A1 (en) 2015-08-06
CA2710762A1 (en) 2009-07-09
AU2008345135A1 (en) 2009-07-09
BRPI0821474A2 (pt) 2017-05-09
BRPI0821474B8 (pt) 2021-05-25
AU2008345135B2 (en) 2014-02-13
TW201731488A (zh) 2017-09-16
BRPI0821474B1 (pt) 2021-03-30
TWI515006B (zh) 2016-01-01
AR069989A1 (es) 2010-03-03
SG187410A1 (en) 2013-02-28
EP2244814A2 (en) 2010-11-03
CN105816858B (zh) 2024-10-18
JP2011508742A (ja) 2011-03-17
JP2014159479A (ja) 2014-09-04
JP2016164199A (ja) 2016-09-08
NZ586383A (en) 2012-11-30
TW200940084A (en) 2009-10-01
CN101952016A (zh) 2011-01-19
CN105816858A (zh) 2016-08-03
US20090192076A1 (en) 2009-07-30
US11191837B2 (en) 2021-12-07
JP5784907B2 (ja) 2015-09-24
KR20160091434A (ko) 2016-08-02
EP3936116A1 (en) 2022-01-12
SG10201608059VA (en) 2016-11-29
TWI600437B (zh) 2017-10-01
EP2244814B1 (en) 2021-06-02
WO2009086400A3 (en) 2009-10-22
WO2009086400A2 (en) 2009-07-09
AU2008345135C1 (en) 2015-04-30
ES2887187T3 (es) 2021-12-22
KR101643277B1 (ko) 2016-07-28

Similar Documents

Publication Publication Date Title
MX2010007150A (es) Formulaciones del factor de von-willebrand recombinante.
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
CY1118360T1 (el) Παρατεταμενης διαρκειας τοπικη αναισθητικη συνθεση η οποια περιεχει saib
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
CY1118496T1 (el) Φαρμακεyτικες συνθεσεις
MX2009007145A (es) Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
CL2010001346A1 (es) Polipeptido mutante del factor de crecimiento de fibroblastos (fgf); multimero que comprende dos o mas copias del polipeptido de fusion antes mencionado; composicion farmaceutica que comprende el polipeptido.
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
TW200745334A (en) Compositions and methods for producing a composition
ATE518534T1 (de) Stabile orale pharmazeutische zusammensetzung mit thyroidhormonrezeptoragonisten
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
EP2496607A4 (en) WOVEN COMPLEXES FOR CYTOKINE RELIEF
WO2008150495A3 (en) Vwf aptamer formulations and methods for use
MY146112A (en) Long-term feed - cancer patient
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
MX2009008542A (es) Agentes de suministro de acido fenilalquilcarboxilico.
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
MX2012006879A (es) Formulacion de aeresol para la enfermedad pulmonar obstructiva cronica.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
TW200635603A (en) Therapeutic formulations of keratinocyte growth factor
DE602008003788D1 (de) Neuartige rar-rezeptoragonisten-liganden und deren verwendung in der humanmedizin und kosmetik

Legal Events

Date Code Title Description
FG Grant or registration